# Oric Pharmaceuticals

Oric Pharmaceuticals is an Asset Manager based in South San Francisco, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** South San Francisco, United States
- **Region:** North America
- **Address:** South San Francisco, CA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** oricpharma.com

## Regulatory record

- **Reports private funds:** No

## About

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) Enozertinib (ORIC-114), a brain penetrant inhibitor designed to selectively target EGFR exon 20, HER2 exon 20 and EGFR atypical mutations in NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

## Sectors

- Digital Health

## Offices

- San Diego, CA, United States

## People

- Jacob Chacko — President and Chief Executive Officer
- Richard Heyman — Chairman of the Board

## Questions

### What is Oric's core scientific focus?

The firm focuses exclusively on the biology of cancer drug resistance. Its pipeline targets specific mechanisms tumors use to evade therapies, including EGFR/HER2 mutations in lung cancer and PRC2 pathways in prostate cancer. The thesis is that by blocking these resistance pathways, Oric's drugs can restore or extend the efficacy of existing treatments.

### Who runs investment decisions at Oric?

Oric does not have an investment committee in the traditional allocator sense—capital allocation decisions are corporate R&D budget decisions made by CEO Jacob Chacko and the executive team, under board oversight chaired by Richard Heyman. Funding is raised through public equity markets rather than LP commitments, and the board approves major expenditures including clinical trial initiations.

### How does Oric source its drug candidates?

Oric uses a hybrid model. Internal medicinal chemistry and biology teams at its South San Francisco and San Diego sites generate proprietary small-molecule inhibitors. The firm also in-licenses promising compounds, as it did with ORIC-114, a brain-penetrant EGFR inhibitor licensed from a South Korean biotech. This mix of internal discovery and external licensing allows it to target resistance mechanisms regardless of chemical origin.

### What is Oric's known posture on co-investments alongside external partners?

Oric does not operate as a co-investor in the typical GP sense. Its collaborations—such as the licensing agreements with Taiho Pharmaceutical—are structured as traditional biopharma licensing deals with upfront payments, milestone payments, and royalties, rather than equity co-investments in portfolio companies.

### Where does the underlying capital for Oric's operations come from?

Oric is publicly traded and funded through equity capital markets. The firm raised $120 million in its April 2020 IPO and has since completed follow-on offerings. Its shareholder base includes institutional biotech investors, not a single-family wealth source. The firm's most recent balance sheet disclosures indicate cash and equivalents sufficient to fund operations into 2026 or early 2027.

## Related profiles

- [Virtus Artificial Intelligence & Technology Opportunities Fund](https://altss.com/profile/virtus-artificial-intelligence-and-technology-opportunities-fund)
- [NB Bancorp](https://altss.com/profile/nb-bancorp-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/oric-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology